Source comparison
BPC-157 for IBS: Research vs Gastric Protection Peptides
Primary Mechanism Angiogenesis + mucosal repair Anti-inflammatory (NF-κB inhibition) Tissue regeneration + immune modulation BPC-157 targets structural healing; KPV reduces inflammation without repair; TB4 overlaps but lacks gut-specific data Evidence Base for
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Angiogenesis + mucosal repair
- Anti-inflammatory (NF-κB inhibition)
- Tissue regeneration + immune modulation
- BPC-157 targets structural healing; KPV reduces inflammation without repair; TB4 overlaps but lacks gut-specific data
- Evidence Base for Gut Applications
- 40+ preclinical studies on gastric/intestinal injury
- Limited. Mostly colitis models
- Minimal gastric research; focused on cardiac/muscle
- BPC-157 has the strongest gastric-specific evidence
- Tested Dosing Range (Animal Models)
- 10 mcg/kg – 10 mg/kg daily
- 0.5–5 mg/kg
- 5–20 mg/kg
- BPC-157 effective at lowest doses; KPV requires higher amounts
- Administration Route
- Subcutaneous, oral (higher dose)
- Oral, topical, subcutaneous
- Subcutaneous only
- Oral BPC-157 works in some models; KPV oral stability unclear
- WADA Status
- Prohibited
- Not listed
- Prohibited (S2 category)
- BPC-157 and TB4 banned in sports; KPV currently unregulated
- Regulatory Approval (Any Country)
- None
- None (except TB4 in equine vet med)
- All three remain research-only for human use as of 2026
- BPC-157 stands apart for gut-specific applications due to sheer volume of gastric ulcer, inflammatory bowel, and mucosal barrier studies. KPV (Lys-Pro-Val) tripeptide shows anti-inflammatory effects in colitis models by blocking NF-κB, but it doesn't promote angiogenesis or structural repair the way BPC-157 does. Thymosin Beta-4 accelerates wound healing systemically, yet published research focuses on cardiac and skeletal muscle. Not gastrointestinal tissue.
- For IBS specifically, no peptide has human trial data. BPC-157's mechanistic overlap with IBS pathophysiology (barrier function, visceral pain modulation, inflammation control) makes it the most biologically plausible candidate, but plausibility isn't efficacy. The compound addresses root mechanisms rather than symptoms, which could explain why anecdotal reports describe delayed onset of effect (2–4 weeks) rather than immediate relief.